Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
Departments of Medicine and Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA. dbauer@psg.ucsf.edu
Douglas C
DC
Bauer
D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000378:metabolism*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D010919:Placebos; D017698:Postmenopause; D010818:Practice Patterns, Physicians'; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D001713:Biphenyl Compounds; D010919:Placebos; D020845:Selective Estrogen Receptor Modulators; C527128:odanacatib